ImmuCell (NASDAQ:ICCC) Releases Earnings Results

ImmuCell (NASDAQ:ICCC) announced its quarterly earnings results on Tuesday. The biotechnology company reported $0.06 EPS for the quarter, Zacks reports. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%.

ImmuCell Stock Performance

Shares of ICCC traded up $0.08 during midday trading on Tuesday, reaching $5.10. 2,267 shares of the stock were exchanged, compared to its average volume of 5,716. ImmuCell has a twelve month low of $3.34 and a twelve month high of $5.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44. The company has a market capitalization of $45.45 million, a price-to-earnings ratio of -10.20 and a beta of 0.54. The business’s 50-day moving average price is $5.11 and its 200 day moving average price is $4.26.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.